Abstract:Background Transarterial chemoembolization (TACE) based neoadjuvant therapy was proven effective in hepatocellular carcinoma (HCC). Recently, tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) also showed promise in HCC treatment. However, the prognostic benefits associated with these treatments remain uncertain. This study aimed to explore the relationship between pathologic response and prognostic features in HCC patients who received neoadjuvant therapy. Methods HCC patients who received TACE either with or without TKIs/ICIs as neoadjuvant therapy before liver resection were retrospectively collected from the First Affiliated Hospital, Zhejiang University School of Medicine in China. Pathologic response was determined by calculating the proportion of non-viable area within the tumor. Major pathologic response (MPR) was defined as the presence of non-viable tumor cells reaching a minimum of 90%. Complete pathologic response (CPR) was characterized by the absence of viable cells observed in the tumor. Results A total of 481 patients meeting the inclusion criteria were enrolled, with 76 patients (15.8%) achieving CPR and 179 (37.2%) reaching MPR. The median recurrence-free survival (mRFS) in the CPR + MPR group was significantly higher than the non-MPR group (31.3 vs. 25.1 months). The difference in 3-year overall survival (OS) rate was insignificant (90.2% vs. 87.6%). Multivariate Cox regression analysis identified failure to achieve MPR (hazard ratio = 1.548, 95% confidence interval: 1.122-2.134; P = 0.008), HBsAg positivity (HR = 1.818, 95% CI: 1.062-3.115, P = 0.030), multiple lesions (HR = 2.278, 95% CI: 1.621-3.195, P < 0.001), and baseline tumor size > 5 cm (HR = 1.712, 95% CI: 1.031-2.849, P = 0.038) were independent risk factors for RFS. Subgroup analysis showed that 67 of 93 (72.0%) patients who received the combination of TACE, TKIs, and ICIs achieved MPR + CPR. Conclusions In individuals who received TACE-based neoadjuvant therapy for HCC, failure to achieve MPR emerges as an independent risk factor for RFS. Notably, the combination of TACE, TKIs, and ICIs demonstrated the highest rate of MPR.

Effect of transcatheter arterial chemoembolization combined with radiofrequency ablation and cytokine-induced killer cells infusion on small hepatocellular carcinoma

Cytokine-Induced Killer (cik) Cell Therapy for Patients with Hepatocellular Carcinoma: Efficacy and Safety

Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.

Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma]

[Cytokine-Induced Killer Cell Fusion to Lower Recurrence of Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization Sequentially Combined with Radiofrequency Ablation: a Randomized Trial].

[Cytokine-Induced Killer Cells Transfusion Following Minimally Invasive and Interventional Therapy for Early-Stage Hepatocellular Carcinoma:A Long-Term Study].

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

[Effect of CIK on long-term survival in the treatment of HCC after RFA combined TACE]

Minimally Invasive Treatment Combined With Cytokine-Induced Killer Cells Therapy Lower The Short-Term Recurrence Rates Of Hepatocellular Carcinomas

Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma.

[Value of CIK in the Treatment of TACE Combined with RFA for HCC in Long-Term Survival and Prognostic Analysis].

A Meta-Analysis of Cytokine-Induced Killer Cells Therapy in Combination with Minimally Invasive Treatment for Hepatocellular Carcinoma.

Adjuvant Cytokine-Induced Killer Cells with Minimally Invasive Therapies Augmented Therapeutic Efficacy of Unresectable Hepatocellular Carcinoma

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for

Autologous Transplantation of Cytokine-Induced Killer Cells As an Adjuvant Therapy for Hepatocellular Carcinoma in Asia: an Update Meta-Analysis and Systematic Review.

The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma: a Meta-Analysis.

TACE Combined with Autologous CIK Cells Treatment on Hepatocellular Carcinoma

A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.

A Randomized Controlled Trial on Patients with or Without Adjuvant Autologous Cytokine-Induced Killer Cells after Curative Resection for Hepatocellular Carcinoma.

719P Tyrosine Kinase Inhibitors And/or Immune Checkpoint Inhibitors is Required for Improving Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Large-Scale Multicenter Real-World Study of 582 Patients